AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Second Quarter Losses Due To Stepped-up Spending on Ovarian Cancer Drug.(Brief Article)
2001 OCT 3 - (NewsRx.com & NewsRx.net) --
AltaRex Corp. (AXO), a developer of antigen-targeted antibody-based cancer therapeutics, reported a net loss of $7.5 million or $0.28 per share for the three months ended June 30, 2001 compared with a net loss of $4.2 million, or $0.27 per share, for the same period in 2000. All dollars reported are Canadian.
For the six-month period ended June 30, 2001, the company recorded a net loss of $13.8 million, or $0.54 per share, compared with a net loss of $8.1 million, or $0.55 per share for the same period in 2000.
The increased net loss is due primarily to the increased spending in manufacturing and clinical development for the company's lead product, OvaRex MAb (oregovomab) for ovarian cancer. The company is scaling up OvaRex production under a development and commercial supply agreement with Abbott Laboratories. The antibody is in the final stages of clinical development prior to the company's filing with the U.S. Food and Drug Administration for accelerated approval of OvaRex MAb.
AltaRex's second quarter progress was highlighted by:
* Important clinical findings with its lead product OvaRex MAb
* Issuance of its cornerstone "multiepitopic" patent in the United States for OvaRex MAb
- OvaRex MAb for Patients with Advanced Ovarian Cancer May Extend Remission...
- Press release article from: Business Wire February 10, 2005 700+ words
...Results of the most recently completed OvaRex MAb clinical study were published in the...treatment" group, patients who received OvaRex MAb experienced a longer period of remission...treatment. "We've learned so much about OvaRex MAb but we now need to confirm these observations...
- ALTAREX PUBLIC OFFERING AND TRIAL PREPARES OVAREX MAB FOR NDA.
- Magazine article from: BIOWORLD Today Pihl-Carey, Karen May 5, 2000 700+ words
...effort to carry the ovarian cancer drug OvaRex MAb through clinical development on its own...interest in partnering with AltaRex on OvaRex MAb and BrevaRex MAb, another anticancer...additional open-label controlled study of OvaRex MAb, which will involve about 150 patients...
- OvaRex MAb Selected as one of 100 Great Investigational Drugs.
- Press release article from: Business Wire May 18, 2004 700+ words
Business Editors EDMONTON, AlbertaBUSINESS WIREMay 18, 2004 AltaRex Medical Corp. (TSX: ALT) ("AltaRex" or the "Company") is pleased to announce that the Company's lead product candidate, OvaRex(R) MAb, has been selected by R&D Directions magazine as one of 100 Great Investigational Drugs. The
- Good Preclinical HBV Data Spur ViRexx Toward Trial.
- Magazine article from: BIOWORLD Today Hollingsworth, Catherine August 20, 2008 700+ words
...trials of its pipeline antibody, OvaRex MAb, for advanced ovarian cancer...arm (standard care followed by OvaRex MAb) and control arm (standard care...quarter. ViRexx recently reported a net loss of C$1.52 million (or C2 cents...
- Orthodontics company announces net loss per share of $0.27.
- Newspaper article from: Medical Devices & Surgical Technology Week March 23, 2003 700+ words
...support our drive to profitability." The net loss for the fourth quarter of 2002, determined...accounting principles was $13.9 million, or a net loss per share of $0.27. This compares to a net loss for the fourth quarter of 2001 of $20...
- OKLAHOMA COUNTY BANKS SHOW COMBINED $9.7 MILLION NET LOSS / FOR FIRST SIX MONTHS
- Newspaper article from: The Journal Record DAVID PAGE October 24, 1987 700+ words
...63 Oklahoma County banks combined for a net loss of $9.7 million for the first six months...of Austin, Texas. That included a net loss of $13.49 million in the second quarter...where the 49 banks reported a combined net loss of $32 million, and Cleveland County...
- XL Capital Ltd Reports Fourth Quarter 2005 Net Loss of $821.9 Million, or a Net...
- Press release article from: PR Newswire February 8, 2006 700+ words
Full Year 2005 Net Loss of $1,292.3 Million, or Net Loss of $9.14 per Ordinary Share Strong Underlying Fundamentals...Capital Ltd ("XL" or the "Company") today reported a net loss to ordinary shareholders for the quarter ended December...
- InforMax Announces Second Quarter Revenue and Net Loss Per Share Results.
- Press release article from: Business Wire August 1, 2001 700+ words
...period. The Company also reported a net loss per share for the second quarter, excluding...compensation, of $(0.16), compared to a net loss per share of $(0.51) for the same period last year. This net loss per share is better than the Company...
Source: HighBeam Research, Second Quarter Losses Due To Stepped-up Spending on Ovarian Cancer...